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Abstract 
 
The platinum-based chemotherapy drugs cisplatin, carboplatin, and oxaliplatin remain, 
despite their long-term use, as integral components in the treatment of more than 25 different 
human cancers. As such, shortages in their supply can have serious health and societal 
impacts on both the outcome and welfare of patients and on the healthcare systems as a 
whole. As all three drugs are no longer under patent protection, they are supplied in 
Australia, the U.S. and the U.K. by between four and 17 different pharmaceutical companies, 
which reduces the risk of drug shortages. Determining the number and impact of platinum 
drug shortages in various regions of the world is difficult because legislation to monitor 
shortages has only been passed recently. All three drugs have suffered from shortages since 
2017 with the most common shortage being due to discontinuation of the drug by the 
company. Other causes include production disruptions, changes in customer demand, 
problems in supply such as transport and storages, and other reasons. The median duration of 
drug shortage is 22 days (shortest and longest supply shortages are 3 and 79 days, 
respectively). Shortages appear to be rare in developed western countries and western 
European countries, but more common in eastern European countries where platinum drugs 
are never available or are available only half of the time. This project highlights the lack of 
information available on platinum drug shortages and the end to further examine platinum 
drug shortages in regions that are more likely to be impacted, such as Africa, south-east Asia, 
central and southern America, and the Middle East. 
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1.1.  Drug shortages 
Drug shortages remain a significant problem throughout the world with many health agencies 
and regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the American 
Society of Health System Pharmacists (ASHP), Health Canada, the Therapeutic Goods 
Administration (TGA) in Australia, and the Institute for Safe Medication Practices (ISMP), 
stating that drug shortages are a chronic and critical problem.1-3 
 
However, there is no consensus on the definition of the term drug shortage. The ASHP 
defines a drug shortage as “a supply problem affecting how the pharmacy prepares or 
dispenses a drug product or influences patient care when prescribers use an alternative 
agent”.2,4 Alternatively, the U.S. FDA defines a drug shortage as when “demand, or projected 
demand, for a medically necessary drug in the United States exceeds it is supply”.1 In 
Australia, the TGA defines a medicine shortages as “when the supply of a medicine is not 
likely to meet the normal or projected consumer demand for the medicine within Australia 
for a period of time”. 
 
 
                                                     Quarters (year) 
Figure 1. Total drug shortages in the USA between 2013 and 2018 as reported by the 
UUDIS.5 
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There is clear evidence that over the last decade the incidence of drug shortages has remained 
significantly high (Figure 1).2,6,7 The number of drug shortages identified by the University of 
the Utah Health Information Service (UUDIS) over the last five years indicates that there has 
been between 174 and 320 shortages of medicines in any given quarter,5,8 and for the most 
recent report period (mid-2018) there were 238 reported shortages.5 
 
The situation in European Union (EU) countries is similar. Between 2010 and 2013, 671 
drugs were listed as being in short supply in seven EU countries.9 In November 2018, the 
European Association of Hospital Pharmacists reported that 38 EU countries experienced a 
drug shortage and that those shortages arose on a daily or weekly basis.10  
 
1.2.  Reasons for drug shortages  
The root causes of drug shortages are complicated and can involve many factors at different 
points of the supply chain. These include: manufacturing issues, regulatory and legislative 
issues, business and market factors, distribution factors, supply and demand issues, natural 
disasters, inventory issues, and human factors.9,11-13 Additionally, each of these factors can be 
influenced by a number of subfactors. An example of a subfactor in a manufacturing supply 
problem is the necessity of manufacturing multiple medicines on a single piece of equipment. 
In this case, there is only limited time available to manufacture and formulate each drug and 
the prioritisation of one drug other another can result in a shortage of the latter drug. 
 
Based on the information provided by the UUDIS in 2018, the cause of almost 50% of all 
drug shortages are unknown (Figure 2). The next most common cause of shortages is due to 
manufacturing problems and the discontinuation of drugs.5  
 
 4 
An example of a drug that was discontinued is the modified release misoprosol pessary. The 
TGA reported in April 2019 that, Ferring Pharmaceuticals Pty Limited would be 
discontinuing the medication, and that their assessment on patient impact was that it would be 
“critical”. The TGA defines a critical impact as “where a shortage of a reportable medicine is 
automatically considered to have a critical patient impact”. Critical patient impacts can be life 
threating as is the case of unexpected heparin shortages for post-surgical patients. 
 
 
                                                    Reasons for shortage 
Figure 2. Sources of drug shortages in 2018 as reported by the UUDIS.5  
 
It is important to also note that drug shortages tend to affect generic drugs more than they 
affect brand name medicines. The reason for this is that, generally, generics produce smaller 
profit margins for companies when compared to brand name medications, and so less effort is 
given to ensure their supply. According to a 2004 survey on the availability of drugs by the 
Jordanian FDA, the median availability of generic medications surveyed in the public sector 
for originator brands was only 27%.14 In a similar survey conducted in 2018, it was found 
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that 77% of Europeans have experienced drug shortages caused by a lack of generic 
medication supply.10 There are also differences in drug shortages when patients are treated in 
public versus private facilities. The availability of the same drugs in the private sector has 
been found to be higher when compared with public facilities, with median availabilities of 
60% and 80%, for both generic drugs and brand drugs, respectively.14  
 
1.3. Reporting of drug shortages 
Although most countries have laws that make reporting of drug shortages mandatory, 
including Australia, how drug shortages are reported varies considerably between countries 
and regions; there are different rules for reporting shortages in the US, Europe, Canada, and 
Australia. Interestingly, Australian data contains more information about shortages when 
compared with the USA or Canada, whereas the lowest level of online data is available for 
Europe (Table 1).  
 
Table 1. Drug shortage management systems in the EU, USA, Canada, and Australia. 
Country  
 
Institution  
 
Type of reporting  Notes 
EU  
 
 
 
USA  
 
 
 
Canada  
 
 
 
Australia  
 
EMA  
 
 
 
FDA  
 
 
 
Health 
Canada 
 
 
 
TGA  
Searchable database 
List of nationally authorized 
medicinal products 
 
Searchable database FDASIA. 
 
ASHP  
 
Shortage overview on 
Website, details for each drug. 
 
 
Searchable database including 
specific criteria. 
 
Independent 
Management Board, 
network organization. 
 
 
Information is available 
via mobile phones 
applications.  
address drug shortage for 
every 24-72 hours. 
Drug shortages report are 
not legally by Health 
Canada not maintain 
binding, and the reasons 
for shortages not always 
listed. 
Reasons for shortages are 
always listed. 
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While companies could voluntarily report drug shortages in Australia for many years, doing 
so only became mandatory at the beginning of 2019 with the passing of the Therapeutic 
Goods Amendment (2018 Measures No 1.) Bill. This legislation provides a nation-wide way 
to manage and communicate medicines shortages through the TGA in an effort to improve 
patient outcomes. 
 
When appropriate, manufacturers are required to notify the US FDA or TGA 12 months in 
advance when they plan to discontinue a specific medicine. In all other instances, a minimum 
of six months is required, and if that is not possible, then a shortage must be reported as soon 
as practicable, but never later than five business days after a discontinuation or interruption in 
manufacturing. The laws require companies to report the expected duration of the shortage, 
the estimated time frame until supply returns to normal, and a reason for the shortage. For 
shortages of over the counter medications the sponsors must tell the TGA about the drug 
shortages within 2-10 business days.  
 
 
1.4.  Chemotherapy drugs  
Chemotherapy is a term used to describe the treatment of cancer with drugs. As the number 
of cancer patients increases each year, the demand for chemotherapy drugs has also 
increased.5  The World Health Organization (WHO) has reported that more than 9.6 million 
people around the world died from cancer in 2018.15 In Australia, the Cancer Council expects 
that by 2040, the number of cancer patients living with, or surviving, the disease will increase 
to almost 1.9 million.16  
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There are many different classes of chemotherapy drugs and many drugs within each 
category. Examples include the antimetabolites (5-fluorouracil and methotrexate), the 
anthracyclines (doxorubicin and daunorubicin), the alkylating agents (carmustine), taxols 
(paclitaxel and docetaxel), the vinca alkaloids (vinblastine and vincristine), and the platinums 
(cisplatin, carboplatin, and oxaliplatin). Chemotherapy drugs are usually used in combination 
to produce higher efficacy compared with monotherapy. They can also be used either before 
(adjuvant) or after (neoadjuvant) surgery or radiation therapy.  
 
1.5.  Shortage of chemotherapy drugs 
Over 65% of hospitalised patients receive some form of chemotherapy as part of their cancer 
therapy;17 therefore, any shortage in chemotherapy drugs can have an impact on cancer 
patients. From data provided by the UUDIS, the percentage of chemotherapy drug shortages 
almost doubled between 2013 and 2017,5 which is an on-going concern in health care.18,19 
When compared to other classes of essential medicines, such as antibiotics, cardiovascular 
medications, antimicrobials, and central nervous system (CNS) drugs, the incidence of 
chemotherapy drug shortages is relatively low. For CNS drugs, there were 36 reported 
shortages in 2018 in the USA for both injectable and non-injectable drugs, but the rate for 
chemotherapy drugs was half that value (Figure 3).5 
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Figure 3. USA shortages by drug class in 2018 as reported by the UUDIS.5  
 
Cancer drugs that have only a small number of manufacturing suppliers are at a higher risk of 
shortages than medications with more than five suppliers, although the relationship between 
the number of drug suppliers and shortages is not linear. The highest risk factor in the supply 
of chemotherapy drugs is the number of years since their approval, as medicines not under 
patent protection yield lower profits and are less likely to be of interest to manufacturers.20,21 
In the USA, the majority of the generic injectable products are supplied by only seven 
companies.22 According to a joint study by the US National Library of Medicine and UUDIS, 
they found that with regard to first line chemotherapy drugs, there is a high possibility of 
shortages in the supply of the medications.20  
 
1.6. Reasons for chemotherapy drugs shortages 
Chemotherapy drug shortages have dramatically increased since 2006;23 however, 
complexities in the chemotherapy supply chain make it difficult to determine the main causes 
for the shortages. One potential significant cause is economics. For instance, the two main 
causes for shortages in the supply of 71 chemotherapy drug as reported in seven European 
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countries were due to manufacturing and economic issues.9 Furthermore, according to the 
TGA, ‘price disclosure policy’ plays a significant role in the shortage of drugs in Australia.  
 
1.7.  Clinical implications of drug shortage in oncology 
1.7.1 Impact on patients 
The impact of a drug shortage on a patient can be significant.24 There have been a number of 
reported instances of chemotherapy drug shortages in the US and Europe which have resulted 
in patients experiencing interruptions or delays in their treatment.25-29 According to a survey 
carried out in the American Medical Society, over 75% of oncologists believe that drug 
shortages lead to inferior patient care.28  In another study, doctors were surveyed and reported 
when they were forced to use alternative treatment regimens. The findings showed that there 
was a 30% reduction in good outcomes for patient and higher rates of side effects (increase of  
34%), when compared cases where the preferred medicines were available.26  
 
1.7.2. Impact on health systems 
Drug shortages can impact not just patients, but also the health care system itself.30,31 
According to information presented by the American Hospital Association dealing with drug 
shortages can be challenging in a number of ways. More than three-quarters of hospitals 
found that dealing with a drug shortage was a major challenge for them (Figure 4). Of the 
remaining respondents, they all considered dealing with drug shortages as a moderate 
challenge. None of the respondents indicate that drug shortages were only a small challenge 
or provided no challenge to their continued provision of health care.  
 
In an American Pharmacist study which set out to examine awareness of drug shortages they 
found that 85% of medication errors occurred when pharmacists used alternative medicines.32 
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In a similar 2011 study, 22% of oncology pharmacists reported that an experience of a drug 
shortage resulted in a medication error at their institution, which included incorrect 
treatments being administered to patients.33  
 
 
                                                          Challenge experience 
Figure 4. Percentage of the challenge experience of drug shortages at U.S. at community 
hospital between 2015 and 2017.2 
 
Some of the challenges faced by the hospitals include having to purchase other, more costly, 
medications as substitutes for the required drugs (Figure 5);2 shortages of cancer drugs 
increase the expenditure rate by up to 80%.34 Drug shortages also cost significant staff time, 
can delay patient treatment, and can even pose significant ethical challenges.10,25 A recent 
survey of pharmacists by the ASHP indicated that pharmacists were spending between eight 
and 12 hours each week and physicians were spending up to two hours each week,  dealing 
with medicines shortages.31 
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Figure 5. Impact of drug shortages on drug spending as reported in the U.S. between 2015 
and 2017. Moderate impact (orange), extreme impact (dark blue), small impact (grey), have 
no idea about the impact (light blue), and no impact (yellow).2 
 
 
1.7.3. Ethical implications of chemotherapy drug shortages 
As the number of chemotherapy drug shortages has grown, several ethical frameworks for 
appropriately rationing these resources have been proposed.35,36 In 2012, the Ontario Ministry 
of Health and Long-Term Care published an ethical framework to guide decision-making 
regarding the redistribution of drug supplies and how to improve health services when drugs 
are in shortage.37 
 
One of the most challenging aspects of dealing with medications in limited supply is how to 
determine which patients warrant higher priority to receive the drugs in question. Cancer is a 
particularly aggressive disease, and a shortage of a drug can likely to result in the relapse of a 
patient. Likewise, a pharmacist or doctor may be faced with the dilemma of having two 
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cancer patients with similar disease progress and likelihood of treatment success but may 
only have enough to treat one patient. In this case, the health care worker is forced into a 
difficult decision on who is more worthy, or the option of potentially splitting the medicine 
and giving both patients a sub-optimal dose.  
 
1.8. Platinum-based chemotherapy drugs 
Platinum-based chemotherapy drugs have been in use for the treatment of human cancers 
since the 1970s. The first drug to be approved was cisplatin, followed by carboplatin in the 
1980s and oxaliplatin in the 1990s (Figure 6).38,39 All three drugs have world-wide approval, 
while there are some platinum drugs that have approval in just single nations, such as 
nedaplatin in Japan, lobaplatin in China, and heptaplatin in Korea.38  
 
 
Figure 6. The chemical structures of the three platinum drugs which have worldwide clinical 
marketing approval: cisplatin, carboplatin, and oxaliplatin.  
 
Platinum drugs are an essential component of many chemotherapy regimens. A recent study 
has shown that platinums are used to treat over 25 types of solid tumours, including 
colorectal, gastrointestinal, gynaecological, head and neck, multiple myeloma, lung and 
urogenital tumours (Table 2).40,41 A recent hospital study has shown that nearly 50% of 
chemotherapy patients receive a platinum drug during their cancer treatment, and some 
patients receive two, and even three, different platinum drugs. Platinum drugs are also used in 
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combination with other antineoplastic drugs such as paclitaxel, fluorouracil, docetaxel, 
gemcitabine, irinotecan or pemetrexed.42  
 
Table 2. The types of cancers that are typically treated with the platinum-based drugs 
cisplatin, carboplatin, and oxaliplatin, based on the chemotherapy protocols in the Australian 
EviQ database.  
Type of cancer Cisplatin Carboplatin
  
Oxaliplatin 
Head and neck 
Gynecological 
Respiratory 
Upper gastrointestinal 
Urogenital 
Colorectal  
Lymphoma  
Sarcoma  
Multiple myeloma 
Bone and marrow transplants 
Breast  
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
No 
No 
No 
Yes 
No 
No 
Yes 
No 
No 
No 
No 
 
1.9.  Mechanism of actions and toxicity of platinum drugs 
All platinum-based chemotherapy drugs are cell cycle non-specific. They act by cross-linking 
DNA via bonding at the N7 site of guanine and adenosine residues. This has the effect of 
inhibiting DNA syntheses and eventually leading to apoptotic cell death.43  
 
Because they act on all rapidly dividing cells, not just cancerous cells, platinum-based 
chemotherapy drugs can induce more than 40 different side effect in patients. The most 
common side effects of platinum, include: anaphylaxis, cytopenia, hepatotoxicity, 
ototoxicity, cardiotoxicity, nausea and vomiting, diarrhea, stomatitis, mucositis, alopecia, 
anorexia, and asthma.  
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As well as the common side effect, each of the platinum drugs has a specific dose-limiting 
side effect. Cisplatin is known to cause severe nephrotoxicity (kidney damage),43,44 whereas 
the major toxicity of carboplatin is myelosuppression (reduction in blood cells). Oxaliplatin’s 
major side effect is peripheral neurotoxicity.  
 
1.10. Knowledge gap 
Cisplatin, carboplatin and oxaliplatin represent the most established and dominant members 
of the platinum drug family. Despite their extensive use for over four decades, little has been 
published on issues regarding their supply and whether shortages can impact patients. 
 
Of the few studies that do exist, most analyse platinum shortages only in the context of larger 
research projects that examine shortages of chemotherapy drugs more broadly. These include 
a study by Salazar et al.21 which examined the impact of cisplatin and other medication 
shortages via the Children's Oncology Group and in local clinical trials. Another study, 
published by McBride et al. used a national online survey to determine the effect of oncology 
drug shortages on cancer care,33 and Hedlund et al. examined the impact of drug shortages on 
patients who were just starting their chemotherapy treatment.45  
 
Understanding shortages of platinum drugs is important in determining the potential impact 
they can have on patients, determining the wider costs and impacts on the healthcare system, 
and drive the development of guidelines for medical staff on what to do in the event of 
shortages of platinum drugs. 
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1.11. Aims of the project 
As it has been discussed, the factors behind drug shortages are multifactorial, and may 
change from region to region, company to company, and from drug to drug. As such, the first 
aim of this thesis was to examine common factors that may lead to shortages in platinum 
drug supply. These include the current state of intellectual property protecting the drugs and 
the number of suppliers of the medication. The second aim was to then examine reported 
drug shortages in different geographical regions, including which drugs have been in short 
supply, for how long they were in short supply, and the reasons behind the shortages.  
 
 
  
 
 
 
 
Chapter Two  
Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 17 
2.1 Study setting and design 
This study sought to examine shortages of only those platinum drugs with world-wide 
approval: cisplatin, carboplatin, and oxaliplatin. Those drugs which only have approval in a 
single country: nedaplatin, heptaplatin, lobaplatin, and miriplatin, were not included in the 
study. 
 
Data was collected through the analysis of the online drug shortage databases of the US FDA 
(including the center for drugs evaluation and research), Health Canada, ASHP, ISMP, 
UUDIS, TGA, and the European Medicines Agency (EMA). Information was also collected 
from pharmaceutical companies which supply platinum drugs. This included analysis of their 
annual reports and company announcements. 
 
Further information was collected through grey literature searching of reports and 
publications on drug shortages available on the internet and data contained in published 
research articles. The journal search strategy utilized medicines and science databases, 
including PubMed and Scifinder Scholar, using word sensitive searches in order to retrieve 
the relevant articles. This included any record containing the words ‘cisplatin’, ‘carboplatin’ 
or ‘oxaliplatin’ in English and the key phrases of ‘platinum drugs’, or cisplatin or carboplatin 
or oxaliplatin ‘plus’ and ‘with’, ‘cancer shortage’ or ‘drug shortage’. 
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3.1. Potential of patent protection to limit supply  
For companies to make a profit from medicines they need to have exclusive rights to 
manufacture and sell specific drugs and formulation. While they can use various intellectual 
property instruments to do this, such as trade secrets and copyrights, the most effective way 
to limit competition is through an international patent. 
 
While each country or region have their own laws regarding the application, filing and 
approval of patents, commonly most patents are granted to inventors for a period of 20 
years.46 On expiry of a patent, other companies can then design and manufacture their own 
generic versions of the drug, usually at a much reduced sale price. 
 
Because branded (patent protected) medicines make significantly more profits for 
companies compared with generic formulation, many companies will seek to find ways to 
extend their patient protection beyond 20 years. Some ways they do this can include 
changing or improving the formulation, changing the solid-state structure of the drug 
(different crystal form or amorphous compared with crystalline), or developing a new 
method for manufacturing the drug.47 
 
Therefore, while the platinum drugs cisplatin, carboplatin and oxaliplatin have been around 
for a number of years, the approval of new patents for these drugs may be used to limit the 
introduction of generics, and through this reduce the number of suppliers, and result in drug 
shortages. It was therefore of interest in this study to examine the current state of patents 
that cover cisplatin, carboplatin and oxaliplatin. Table 3 provides examples of relevant 
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international patents that cover the three platinum drugs used world-wide. The table 
excludes those patents that are for derivatives of the drugs or those patents that relate to 
unique drug delivery formulations that include a platinum drug (i.e. nanoparticle or similar 
drug delivery formulations). 
 
Table 3. Examples of international patents that cover the use of molecular carboplatin, and 
oxaliplatin for the treatment of cancers in humans. 
Drug Original 
Filing 
Year 
Country Patent No Notes 
Carboplatin 1972 USA US 4140707 Original patent that included 
carboplatin 
Oxaliplatin 1976 Japan 27818/1976 Original patent describing 
oxaliplatin as a potential 
anticancer drug 
Oxaliplatin 1992 Japan EP 617043 Better method of 
synthesizing oxaliplatin 
Oxaliplatin 1998 France WO 99/43355 Development of more stable 
formulations of oxaliplatin 
Oxaliplatin 2005 USA WO 2005/102312 Development of concentrated 
oxaliplatin solutions 
 
It is not clear when cisplatin as a potential chemotherapy drug was first patented. While it 
was first synthesized in 1845 by chemist Michel Peyrone, the patent for its use in cancer 
treatment must predate Rosenberg’s reporting of the drug in the journal nature in 1965. 
What it known is that cisplatin started its first clinical trial in 1971 and was given marketing 
approval in the USA in 1978. As such, patent protection of cisplatin is unlikely to have an 
effect on its availability to patients in our current era. 
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The drug carboplatin was also developed by Rosenberg and colleagues at Michigan State 
University. It was first patented in 1972 and gained marketing approval in 1986. Similar to 
cisplatin, patent protection of carboplatin has long since lapsed and should not affect its 
availability to patients. 
 
Only four years after the patent for carboplatin, oxaliplatin was patented in Japan in 1976. 
Interestingly, while the patent should have lapsed in the mid-1990s, the drug only came to 
market through Sanofi-Aventis in 1996.38 The company however managed to maintain a 
monopoly in the market until 2012 through the filing on additional formulation patents. In 
the 2000s six generics manufacturers attempted to introduce their own formulations in the 
US. These companies manufactured oxaliplatin until 2010, at which time they were forced 
to discontinue supply. Generic formulations of oxaliplatin were then reintroduced in 2012. 
A search of the current literature has not revealed any current patents which restrict 
manufacturers from supplying generic products, and as such, this is not expected to impact 
on the supply of the drug to patients. 
 
Overall, despite recent patent protection of oxaliplatin, all three drugs are available to be 
manufactured by generics companies, and drug shortages are not expected due a limitation 
in the number of potential suppliers. 
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3.2 Current suppliers  
Given the lack of current patent protection of cisplatin, carboplatin and oxaliplatin, we next 
sought to determine the total number of companies that supply both generic and branded 
formulations of the drugs for the world-wide market. The results are presented in Table 4. 
 
Table 4. Cisplatin, carboplatin, and oxaliplatin suppliers from 2003 to 2014.20 
Year 
Drug 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Cisplatin 5 5 5 4 3 3 3 3 3 2 3 4 
Carboplatin 1 1 5 8 9 8 9 7 6 5 4 5 
Oxaliplatin 1 1 1 1 1 1 1 4 5 5 7 7 
 
Since the 2003-2014 study the number of suppliers approved to sell platinum-based 
chemotherapy drugs have increased significantly. A full list of companies that supply 
platinum drugs is provided at appendix 1. 
 
In Australia there are four suppliers for cisplatin, six for carboplatin, and 12 for oxaliplatin 
(Table 5). For cisplatin the numbers of suppliers are 9 and 8 for the USA and UK 
respectively, for carboplatin they are 17 and 8, and for oxaliplatin the number of suppliers are 
17 and 11, respectively, in the USA and UK (Tables 6 and 7). 
 
A general trend can be seen where on average the fewest suppliers are for cisplatin, the oldest 
of the four drugs and potentially the drug in lowest demand. Oxaliplatin is manufactured by 
the highest number of suppliers which may reflect the growing importance of this drug in 
oncology as there appears to be little difference in the price (and hence profit) of the drugs. 
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Taking DPMA (dispensed price maximum amount) prices listed from the Australian 
Pharmaceutical Benefits scheme, the price per 100 mg of cisplatin is $58-77, which is higher 
than the price per 100 mg for carboplatin ($17-22) and per 100 mg of oxaliplatin ($47-61). 
 
Overall, the number of platinum drug suppliers in each of the three countries appears to have 
significant in-built redundancy such that if one or two companies were unable to provide 
their formulation, then there are sufficient other suppliers to ensure accessibility to patients. 
 
Table 5. Suppliers of platinum drugs in Australia as listed on the Australian Register of 
Therapeutic Goods in June 2019. (a) indicates those suppliers whose formulations are listed 
on the Pharmaceutical Benefits Scheme. 
Cisplatin Carboplatin Oxaliplatin 
Accorda Accorda Pfizera 
Hospiraa Hospiraa Accorda 
Pfizer Pfizer Sun Pharmaa 
Sandoz Teva Sandoza 
 Fresenius Kabi Wockhardt Bio 
 Novotech Hospira 
  Apotex 
  Alphapharm 
  Juno Pharm 
  Medis 
  Link Medical Products 
  Sanofi-Aventis 
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Table 6. Suppliers of platinum drugs in the U.S. as registered with the US FDA in June 2019. 
Cisplatin Carboplatin Oxaliplatin 
HQ SPCLT Pharma West-Ward Teva 
PharmaChemie Watson Labs Sanofi-Aventis 
Bedford Fresenius Kabi Actavis 
Fresenius Kabi Hospira Fresenius Kabi 
Teva Pliva Sandoz 
West-Ward Sandoz Hospira 
Mylan Teva Mustafa Nevsat 
Accord PharmaChemie Sun Pharma 
Gland Pharma Cipla Pliva 
 Sun Pharma Jiangsu Hengrui 
 Actavis Qilu Pharm 
 Akorn Luitpold 
 Mylan Eugia Pharma 
 Eugia Pharma Gland Pharma 
 Gland Pharma Accord 
 Ingenus Pharms Cipla 
 Corden Pharma Ingenus Pharms 
 
Table 7. Suppliers of platinum drugs in the UK as registered with the Medicines and 
Healthcare Regulatory Agency in June 2019. 
Cisplatin Carboplatin Oxaliplatin 
Teva Hikma Farmaceutica Hospira 
Accord Fresenius Kabi Sanofi 
Ebewe Pharma Accord Aventis Pharma 
Fresenius Kabi Fannin Teva 
Caduceus Pharma Cipla Lek Pharmaceuticals 
Sandoz Teva Fresenius Kabi 
Cipla Hospira Sun Pharmaceutical Industries 
Pharmacia Ebewe Pharma Torrent Pharma 
  Aptil Pharma 
  Sandoz 
  Ebewe Pharma 
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3.3 Incidence, duration, and causes for platinum drug shortages in 
Australia, U.S. and U.K.  
Next, we sought to examine the prevalence of drug shortages and disruptions to supply that 
have been reported in various countries. As was discussed in chapter 1, Australia, the U.S. 
and the UK recently introduced legislation making the reporting of drug shortages mandatory 
for pharmaceutical companies. Before, companies were able to voluntarily report shortages. 
Table 8 provides the details of all reported shortages for platinum drugs (including where the 
manufacturer has decided to cease production) in each of the three main countries of interest. 
 
While companies are required to report the cause of drug shortages, they are not required to 
provide specific details on the nature of the shortage. As can be seen in the table 8, drug 
shortages can result from discontinued production, disruptions in production, a change 
(increase) in patient demand, and problems in supply (such as transport and storage).  
 
For those drug shortages which do not include discontinuation, they are relatively short lived. 
The shortest and longest periods for a reported shortage were 3 and 79 days, respectively. 
The median length of shortage was 22 days, which is not expected to have a significant effect 
on patient outcomes.  
 
When a company discontinues a platinum-drug the reasons behind the decision are usually 
not known. From an analysis of the annual reports for those companies that advised that they 
were discontinuing production, no reason behind the decision could be found. A similar result 
was obtained when each company’ public announcements were searched. 
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Table 8. Reported drug shortages and disruptions to supply from 2017 onwards as reported to 
the TGA in Australia, Health Canada, the U.S. FDA, and the U.S. ASHP. 
Drug Size Country Company Start End Reason 
Cisplatin 50 mL USA Mylan Jan 2018 N/A Discontinued 
production 
Cisplatin 100 mL USA Mylan Jan 2018 N/A Discontinued 
production 
Carboplatin 20 mL USA Mylan Jan 2018 N/A Discontinued 
production 
Carboplatin 40 mL USA Mylan Jan 2018 N/A Discontinued 
production 
Carboplatin 50 mL USA Mylan Jan 2018 N/A Discontinued 
production 
Carboplatin 100 mL USA Mylan Jan 2018 N/A Discontinued 
production 
Carboplatin 15 mL Canada Pfizer 26 Oct 2017 09 Nov 2017 Disruption to 
manufacture 
Carboplatin 60 mL Canada Pfizer 16 Apr 2018 19 Apr 2018 Disruption to 
manufacture 
Cisplatin 100 mL Canada Accord 
Healthcare 
06 Mar 2017 30 Mar 2017 Disruption to 
manufacture 
Oxaliplatin 10 mL Canada Pfizer 13 Apr 2017 20 Jun 2017 Discontinued 
production 
Oxaliplatin 40 mL Canada Pfizer 18 Aug 2017 20 Sep 2017 Demand 
increase for the 
drug 
Oxaliplatin 10 mL Canada Teva 18 Jun 2019 Est 30 Jun 
2019 
Discontinued 
production 
Oxaliplatin 20 mL Canada Teva 18 Jun 2019 Est 30 Jun 
2019 
Discontinued 
production 
Oxaliplatin 10 mL Canada Sandoz 11 Jul 2017 28 Jul 2017 Delay in 
shipping 
Oxaliplatin 20 mL Canada Sandoz 17 May 2017 28 July 2017 Other (limited 
inventory 
available to our 
customers) 
Oxaliplatin 40 mL Canada Sandoz 20 Jan 2017 11 Apr 2017 Delay in 
shipping 
Oxaliplatin 40 mL Canada Sandoz 17 May 2017 01 Sep 2017 Other (limited 
inventory 
available to our 
customers) 
Oxaliplatin 10 mL Australia Sun Pharma 15 Dec 2018 N/A Discontinued 
production 
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A potential reason for a company to discontinue the supply of platinum drugs may be due to 
the cost of raw materials and their ability to manufacture at a profit. For most organic-based 
drugs, the major costs of manufacture are facilities and staff, but for cisplatin, carboplatin, 
and oxaliplatin the cost of raw materials would be expected to affect profits to a larger extent.  
 
Platinum is considered a precious metal with only 160,000 tonnes of the material being 
mined each year.48 As such, the cost of platinum metal is very high. In June 2019 the spot 
price of platinum was US$814 per ounce, which is more than 50 times higher than the price 
of silver, but only 58% the cost of gold. However, based on the price of platinum, it appears 
that it is not contributing factor in company decision to cease cisplatin, carboplatin, or 
oxaliplatin production. The price of platinum reached a peak in September 2011 at a price of 
US$1,852 per ounce, and has since fallen by 44%. This does not include the effect of 
inflation which would have a further downward effect on the cost of platinum. As such, the 
raw material cost to produce platinum drugs has only gone down over the last decade, not up. 
 
3.4 Incidence of platinum drug shortages in eastern European nations 
In November 2018, while the study described by this thesis was underway, the European 
Society for Medical Oncology published their report titled Availability of medicines: Impact 
on public health.10 
 
In this report, the committee analysed the availability of chemotherapy drugs that are listed 
by the WHO as essential medicines. Their list includes cisplatin as an essential medicine in 
the treatment of lung, ovarian, gastrointestinal tract cancers, and sarcomas. Carboplatin is 
listed as an essential medicine for breast, ovarian, and lung cancers, and oxaliplatin is listed 
as an essential medicine for colorectal cancer.49  
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Their report, which provides the availability of the platinum drugs in 48 individual nations, 
separates the countries based on geographical location by western and eastern Europe. With 
this grouping a significant and interesting observation on platinum shortages can be made. 
 
For the 21 countries making up the western European group there were only two countries 
that did not report that all three platinum drugs were always available. Greece reported that 
cisplatin was only usually available for the treatment of sarcomas, and carboplatin was only 
available half of the time for breast cancer treatment. Australia reported that cisplatin was 
only usually available for the treatment of ovarian cancer. No western European country 
reported a problem with shortages for oxaliplatin. 
 
In contrast, for those countries in eastern Europe, shortages were far more common. Of the 
27 countries in this group, eight reported that cisplatin was only usually available, three 
reported that cisplatin was only available half of the time, and once country (Armenia) 
reported that it was never available. 
 
For carboplatin, the statistics are worse. Eight countries reported that it was usually available,  
three reported it was available half the time, two reported that it was occasionally available, 
and three countries (Armenia, Serbia and Slovenia) reported it was not available (i.e. not 
approved for sale or no companies have made any available for sale). Only 13 of the 27 
nations reported that carboplatin was always available for patients. 
 
For oxaliplatin the results are slightly better. Seventeen of the 27 nations stated that the drug 
was always available. Of the other ten, eight reported that is was usually available, one stated 
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it was available only half of the time (Armenia), and one stated that it was never available 
(Macedonia). 
 
These results highlight a problem that is not observed in western countries and western 
European countries, and may hint at a larger problem in other regions. Other potential at risk 
regions, for which there is no data, are central and southern America, south-east Asia, Africa, 
and Middle Eastern countries. 
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Chapter Four 
Conclusions and Future Work 
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The platinum-based chemotherapy drugs cisplatin, carboplatin, and oxaliplatin remain a 
crucial component in the treatment plan of many human cancer patients. As such, shortages 
of these drugs have the potential to impact patient outcomes and the provision of healthcare 
more broadly.  In this thesis we examined the current state of platinum drug shortages in the 
world. 
 
As all three drugs are off-patent they are widely available and in the three main regions of 
interest Australia, U.S., and the U.K., between 4 and 17 companies provide supply of the 
drugs. Where drug shortages are reported, these tend to be of short duration (median 22 days) 
and are caused by production disruptions, companies deciding to discontinue supply, changes 
in customer demand, problems in supply such as transport and storage, and other reasons. 
 
While shortages are rare in western countries and western European countries, shortages of 
platinum drugs in eastern European countries is common. Some countries have reported 
never having available stocks of one or more platinum drugs. 
 
The results of this thesis indicate that for those patients in Western countries the impact of 
platinum drug shortages is minor, but for patients in other regions (especially Eastern 
Europe) there is significant evidence that shortages will affect patient long term survival. 
What is now needed are government and health plans to what do in the instance of a platinum 
shortage, and supply chain solutions to minimise the number and length of platinum drug 
shortages. 
 
In continuing this research a number of potential projects are recommended. The first is to 
examine whether there are any reported shortages for those drugs that are used in only single 
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nations. This would include nedaplatin, heptaplatin, lobaplatin, and miriplatin. The results for 
these drugs, given the presumably lower number of manufacturers, may be in contrast to the 
results found for cisplatin, carboplatin, oxaliplatin. This may especially be the case given the 
newest drug, miriplatin, is likely to still be under patent protection.  
 
A second recommendation is that further work seeks to examine drug shortages in regions 
more likely to have trouble accessing platinum drugs. This could include central and south 
America, south-east Asia, Africa, and the Middle East. 
 
If the second recommendation is adopted, then the final recommendation would be to also 
examine the impact on platinum drug shortages on patients in those identified regions. This 
would include looking at patient outcomes (overall five year survival rates), and how medical 
staff work around platinum drug shortages. 
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drugs 
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Table S1. Current manufactures of cisplatin chemotherapy drugs. 
Brand/Generic Country  
 
Company 
Cisplatin 
Cisplatin 
Cisplatin 
Platinol®-AQ 
Cisplatin 
Cisplatin 
Cisplatin 
Cisplatin  
Cisplatin 
Cisplatin 
Cisplatin 
Cisplatin 
Platinol 
Cisplatin 
Cisplatin 
Cytoplatin 
Cisplat 
Platin 
Platikem Nova  
UK 
United States 
United States 
United States 
United States 
United States 
United States 
Australia 
United States 
India 
Canada 
United States 
United States 
United States 
India 
India 
India 
India 
India 
Acoord 
Pfizer  
Mylan Pharmaceuticals 
Teva 
WG Critical 
Fresenius Kabi 
Alvogen 
Hospira Pty Limited 
Gland Pharma 
GLS Pharma Ltd 
Sandoz  
Blue Point Laboratories 
Athenex Pharmaceutical Division, Llc. 
Spectrum Pharmaceuticals 
Taj Pharma 
Cipla  
Zydus Cadila 
Cedila pharmacuticals Ltd 
Alkem Laboratories Ltd 
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Table S2. Current manufactures of carboplatin chemotherapy drugs. 
Brand/Generic Country 
  
Company 
Carboplatin 
Carboplatin 
Carpoplate 
Carboplatin 
Carboplatin 
Carboplatin 
Carboplatin  
Carboplatin 
Carboplatin  
Carboplatin 
Womastin 
Biocarb 
Carboplatin 
Carbpa 
Carmuta 
Paraplatin 
Stricarb  
Carbosin 
Carboplatin 
Carboplatin 
Carboplatin 
Carboplatin 
Carboplatin 
Carbosol 
UK 
Australia 
United States 
United States 
United States 
United States 
United States 
United States 
India 
India 
India 
India 
India 
India 
India 
India 
India 
South Africa 
India 
India 
United States 
China 
United States 
Austria 
Acoord 
Hospira Pty Limited 
Pfizer  
Mylan Pharmaceuticals 
Teva 
Alvogen 
Gland pharma 
Sagent 
GLS Pharma Ltd 
Cipla  
Alkem Laboratories Ltd. 
Zydus Cadila  
Dr.Reddy's Laboratories 
Intas Pharmaceutical Ltd. 
Emcure Pharmaceuticals Ltd. 
BMS  
Strides Shasun Ltd. 
Pharmachemie Bv  
West-Ward Pharms   
Eugia Pharma 
Akron 
Hong Kong  
Sanja Pharmaceuticals 
Sanova 
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Table S3. Current manufactures of oxaliplatin chemotherapy drugs. 
Brand/Generic Country  
 
Company 
Oxaliplatinum 
Oxaliplatin 
Oxaliplatin  
Oxaliplatin 
Oxaliplatin 
Oxaliplatin 
Oxaliplatin 
Oxaliplatin 
Oxaliplatin  
Eloxatin® 
Elplat 
Oxaliplatin 
Oxaliplatin  
X-PLAT  
Oxaliplatin WKT 
Oxaliplatin  
ELOXATIN® 
Oxaliplatin 
ELOXATIN® 
PMS-Oxaliplatin 
Oxaliplatin 
Oxaliplatin 
Oxaliplatin 
UK 
United States 
United States 
United States 
United States 
United States 
United States 
United States 
Germany 
New Zealand 
Japan 
India 
India 
United States 
Australia  
Australia  
Canada 
India 
China 
Canada 
China 
United States 
Switzerland 
Acoord 
Pfizer  
Mylan Pharmaceuticals 
Bedford Pharmaceuticals 
Teva 
Fresenius Kabi 
Alvogen 
Gland Pharma 
Sandoz 
Sanofi Aventis 
Yakult Honsha 
GLS Pharma Ltd. 
Dr.Reddy's Laboratories 
Cipla Limited 
Wockhardt Bio Pty Ltd 
Hospira Pty Ltd 
Apotex Pty Ltd 
Cipla  
Qilu Pharmaceutical  
Pharmascience 
Jiangsu Hengrui Med 
Actavis LLC 
Eugia pharma 
 
 
 
 
 
 
 
 
 
 
 
